Even by the standards of today's medical device world, the acquisition last year of Plus Orthopedics Holdings by Smith & Nephew was impressive. Perhaps it was the deal's value: by any measure, one billion Swiss francs (or just under $900 million) simply has a nice ring to it. Perhaps it was the deal's European provenance: rarely in Europe do small start-ups grow to a size to justify such a valuation. But if the deal was anything but typical, the story behind Plus seems almost textbook.
by David Cassak
Even by the standards of today’s medical device world, the acquisition last year of Plus Orthopedics AG by Smith & Nephew PLC was impressive. [See Deal] Perhaps...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
